Zelira receives $1,070,000 R&D Tax Incentive Scheme Refund

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development of clinically validated cannabis medicines, advises that it has received a $1,070,000 cash refund under the Federal Government’s Research and Development Tax Incentive Scheme. As announced on 24 July 2025, the Company entered into a loan agreement with Rocking Horse Capital for $650,000 as an advance against its FY2